Yellow Fever – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Yellow Fever Market Outlook
Thelansis’s “Yellow Fever Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Yellow Fever treatment modalities options
for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and
China).
Yellow Fever Overview
Yellow
fever is an acute viral hemorrhagic disease caused by the flavivirus, closely
related to the viruses that cause West Nile, St. Louis, and Japanese
encephalitis. Tree-hole breeding mosquitoes, such as Aedes aegypti and
Haemagogous species, primarily transmit it. The transmission of the virus
occurs in three distinct cycles: jungle, intermediate, and urban. The
incubation period is typically 3 to 6 days, and once contracted, the virus
quickly spreads to multiple organs in the body, with the liver and kidneys
being the most affected. Symptoms include jaundice, acute renal failure, black
vomit, cerebral edema, and encephalopathy. There is no specific treatment for
yellow fever, but severe cases require aggressive supportive care and
hydration. The differential diagnosis for yellow fever includes a variety of
other infectious diseases, such as viral hemorrhagic fevers, viral hepatitis,
and malaria. Most cases of yellow fever are subclinical or mildly symptomatic,
with an excellent prognosis, but the severe disease can occur in 15% of
symptomatic patients, with a death rate of 30-50%.
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for
target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment